License and supply agreement with Genuine Health
RNS & Investor News
Completion of Placing & Total Voting Rights
21 December 2015
OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that the 2,000,000 new ordinary shares issued subsequent to the placing, which was announced on 7 December 2015, have today been admitted to trading on AIM and that the placing has therefore completed.
Total Voting Rights
Further to the completion of the placing and the issue and admission of a further 375,000 new ordinary shares subsequent to the exercise of warrants announced on 11 December 2015, the issued share capital of the Company now comprises 76,226,925 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
As described in the Company's admission document dated 18 July 2014 (which is available on the Company's website), a concert party ("CP") at that time held 39.7 per cent. of the Company's issued share capital and had a maximum potential shareholding of 46.5 per cent. in the event that options and warrants held by CP members were exercised.
Following completion of the placing and issues of equity set out above, the CP members' current shareholding and maximum potential shareholding (in the event that options and warrants as set out in the admission document were exercised) are set out in the table below.
|Current shareholding||Number of options / warrants held||Maximum potential shareholding|
|Number of Ordinary Shares||%||Number of
|Finance Yorkshire Seedcorn Fund||12,598,238||16.5||-||12,598,238||14.8|
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
|Tel: 020 7148 7900|
|Hybridan LLP (Joint Broker)
Claire Louise Noyce
|Tel: 020 3713 4581|
|Peterhouse Corporate Finance Ltd (Joint Broker)
Lucy Williams / Duncan Vasey
|Tel: 020 7469 0936|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020